Sartorius signs Pact to improve use and recycling of plastics

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is the first company in its sector to sign the European Plastics Pact. The objective of this public-private coalition is to improve use and recycling of plastics and thus to reduce usage of new plastic. Through cross-border cooperation at the European level, the signatories of this Pact aim to develop new techniques and approaches, share knowledge, harmonize guidelines and standards, and reduce current barriers. The European Plastics Pact was introduced on Friday in Brussels, Belgium, in the presence of ministers from several EU countries, the participating companies, and Frans Timmermans, Vice President of the European Commission, among other attendees.

Single-use plastic products for use in biopharmaceutical research and production usually have a better ecological footprint than do comparable reusable products. Still, we see potential to reduce the use of natural resources in this area. Materials and material flows designed for recycling will play a key role in this context. In view of sophisticated product functionality and product safety, this is certainly a complex subject in the biopharmaceutical industry. The European Plastics Pact as a cooperative initiative on an international level fits in with our proactive sustainability approach.”

Joachim Kreuzburg, Executive Board Chairman and CEO, Sartorius

According to the European Plastics Pact, global use of plastics has increased twenty-fold over the past 50 years and is still growing. Even though waste resulting from biopharmaceutical single-use technologies accounts for only around 0.01 percent of the volume of annual plastic waste generated, the question of responsible use of plastics is increasingly being raised in the biopharma industry as well, given the steady growth of this market. Use of plastics often provides not only economic benefits but also considerable ecological advantages, especially as less water and energy are consumed than needed for cleaning of reusable equipment. Particularly in the pharmaceutical and biopharmaceutical industries, single-use plastic products moreover provide vital safety benefits for patients.

To align single-use technologies that are beneficial for the biopharma industry with environmental aspects, Sartorius is developing a strategy for plastics that is oriented toward the four aspirational objectives of the European Plastics Pact:

Reusability and recyclability

Plastic packaging will be designed to be reusable where possible and in any case recyclable. The design of functional single-use plastic products will focus on recyclability as far as possible.

Responsible use of plastics

Virgin plastic materials will be reduced.

Collection, sorting and recycling

The recycling rate will be increased by collection and sorting.

Use of recycled plastics

Recycled plastics will be used for packages and products whenever possible and appropriate.

You will find further details on the objectives and the list of the signatories of the European Plastics Pact here:



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sartorius. (2020, March 09). Sartorius signs Pact to improve use and recycling of plastics. News-Medical. Retrieved on May 24, 2024 from

  • MLA

    Sartorius. "Sartorius signs Pact to improve use and recycling of plastics". News-Medical. 24 May 2024. <>.

  • Chicago

    Sartorius. "Sartorius signs Pact to improve use and recycling of plastics". News-Medical. (accessed May 24, 2024).

  • Harvard

    Sartorius. 2020. Sartorius signs Pact to improve use and recycling of plastics. News-Medical, viewed 24 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SwiftScale Biologics: Cell-Free Synthesis of Biologics